Novel viral vector systems for gene therapy

Viruses

Volumn 2, Issue 4, 2010, Pages 1002-1007

  Stone, Daniel ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; VIRUS VECTOR;

ARTICLE; ENCAPSULATION; GENETIC MANIPULATION; HERPES SIMPLEX VIRUS; HUMAN; NONHUMAN; PATIENT SAFETY; RISK ASSESSMENT; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 79952177773     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2041002     Document Type: Article

References (18)

1. Kohn, D.B.; Sadelain, M.; Glorioso, J.C. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer 2003, 3, 477-488.
2. Cavazzana-Calvo, M.; Fischer, A. Gene therapy for severe combined immunodeficiency: are we there yet? J. Clin. Invest. 2007, 117, 1456-1465.
3. Somia, N.; Verma, I.M. Gene therapy: trials and tribulations. Nat. Rev. Genet. 2000, 1, 91-99.
4. Bainbridge, J.W.; Smith, A.J.; Barker, S.S.; Robbie, S.; Henderson, R.; Balaggan, K.; Viswanathan, A.; Holder, G.E.; Stockman, A.; Tyler, N.; Petersen-Jones, S.; Bhattacharya, S.S.; Thrasher, A.J.; Fitzke, F.W.; Carter, B.J.; Rubin, G.S.; Moore, A.T.; Ali, R.R. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 2008, 358, 2231-2239.
5. Cideciyan, A.V.; Aleman, T.S.; Boye, S.L.; Schwartz, S.B.; Kaushal, S.; Roman, A.J.; Pang, J.J.; Sumaroka, A.; Windsor, E.A.; Wilson, J.M.; Flotte, T.R.; Fishman, G.A.; Heon, E.; Stone, E.M.; Byrne, B.J.; Jacobson, S.G.; Hauswirth, W.W. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. USA 2008, 105, 15112-15117.
6. Aiuti, A.; Cattaneo, F.; Galimberti, S.; Benninghoff, U.; Cassani, B.; Callegaro, L.; Scaramuzza, S.; Andolfi, G.; Mirolo, M.; Brigida, I.; Tabucchi, A.; Carlucci, F.; Eibl, M.; Aker, M.; Slavin, S.; Al-Mousa, H.; Al Ghonaium, A.; Ferster, A.; Duppenthaler, A.; Notarangelo, L.; Wintergerst, U.; Buckley, R.H.; Bregni, M.; Marktel, S.; Valsecchi, M.G.; Rossi, P.; Ciceri, F.; Miniero, R.; Bordignon, C.; Roncarolo, M.G. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 2009, 360, 447-458.
7. Gene Therapy Clinical Trials Worldwide. http://www.wiley.co.uk/genetherapy/clinical/ (accessed 7 April 2010).
8. Stone, D.; Lieber, A. New serotypes of adenoviral vectors. Curr. Opin. Mol. Ther. 2006, 8, 423-431.
9. Blaese, R.M.; Culver, K.W.; Miller, A.D.; Carter, C.S.; Fleisher, T.; Clerici, M.; Shearer, G.; Chang, L.; Chiang, Y.; Tolstoshev, P.; Greenblatt, J.J.; Rosenberg, S.A.; Klein, H.; Berger, M.; Mullen, C.A.; Ramsey, W.J.; Muul, L.; Morgan, R.A.; Anderson, W.F. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 1995, 270, 475-480.
10. Brenner, M.K.; Rill, D.R.; Moen, R.C.; Krance, R.A.; Mirro, J., Jr.; Anderson, W.F.; Ihle, J.N. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993, 341, 85-86.
11. Hacein-Bey-Abina, S.; Von Kalle, C.; Schmidt, M.; McCormack, M.P.; Wulffraat, N.; Leboulch, P.; Lim, A.; Osborne, C.S.; Pawliuk, R.; Morillon, E.; Sorensen, R.; Forster, A.; Fraser, P.; Cohen, J.I.; de Saint Basile, G.; Alexander, I.; Wintergerst, U.; Frebourg, T.; Aurias, A.; Stoppa-Lyonnet, D.; Romana, S.; Radford-Weiss, I.; Gross, F.; Valensi, F.; Delabesse, E.; Macintyre, E.; Sigaux, F.; Soulier, J.; Leiva, L.E.; Wissler, M.; Prinz, C.; Rabbitts, T.H.; Le Deist, F.; Fischer, A.; Cavazzana-Calvo, M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302, 415-419.
12. Gomez, C.E.; Najera, J.L.; Krupa, M.; Esteban, M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 2008, 8, 97-120.
13. Daya, S.; Berns, K.I. Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev. 2008, 21, 583-593.
14. Mueller, C.; Flotte, T.R. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 2008, 15, 858-863.
15. Berges, B.K.; Wolfe, J.H.; Fraser, N.W. Transduction of brain by herpes simplex virus vectors. Mol. Ther. 2007, 15, 20-29.
16. Cattaneo, R.; Miest, T.; Shashkova, E.V.; Barry, M.A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat. Rev. Microbiol. 2008, 6, 529-540.
17. Manno, C.S.; Pierce, G.F.; Arruda, V.R.; Glader, B.; Ragni, M.; Rasko, J.J.; Ozelo, M.C.; Hoots, K.; Blatt, P.; Konkle, B.; Dake, M.; Kaye, R.; Razavi, M.; Zajko, A.; Zehnder, J.; Rustagi, P.K.; Nakai, H.; Chew, A.; Leonard, D.; Wright, J.F.; Lessard, R.R.; Sommer, J.M.; Tigges, M.; Sabatino, D.; Luk, A.; Jiang, H.; Mingozzi, F.; Couto, L.; Ertl, H.C.; High, K.A.; Kay, M.A. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 2006, 12, 342-347.
18. Raper, S.E.; Chirmule, N.; Lee, F.S.; Wivel, N.A.; Bagg, A.; Gao, G.P.; Wilson, J.M.; Batshaw, M.L. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 2003, 80, 148-158.